Summary of adverse events
| Type of AE . | Cohort 1a: 25 mg/m2 MWF (n = 33) . | Cohort 1b: 37.5 mg/m2 MWF (n = 83) . | Cohort 1c: 25/25/50 mg/m2 MWF (n = 51) . | Total (N = 167) . |
|---|---|---|---|---|
| Any treatment-related AE | 21 (64) | 66 (80) | 37 (73) | 124 (74) |
| Any treatment-related grade 3/4 AE | 14 (42) | 46 (55) | 26 (51) | 86 (51) |
| Any treatment-related serious AE | 5 (15) | 28 (34) | 12 (24) | 45 (27) |
| Any treatment-related AE leading to study drug discontinuation | 2 (6) | 14 (17) | 5 (10) | 21 (13) |
| Any treatment-related AE leading to death | 0 | 0 | 0 | 0 |
| Type of AE . | Cohort 1a: 25 mg/m2 MWF (n = 33) . | Cohort 1b: 37.5 mg/m2 MWF (n = 83) . | Cohort 1c: 25/25/50 mg/m2 MWF (n = 51) . | Total (N = 167) . |
|---|---|---|---|---|
| Any treatment-related AE | 21 (64) | 66 (80) | 37 (73) | 124 (74) |
| Any treatment-related grade 3/4 AE | 14 (42) | 46 (55) | 26 (51) | 86 (51) |
| Any treatment-related serious AE | 5 (15) | 28 (34) | 12 (24) | 45 (27) |
| Any treatment-related AE leading to study drug discontinuation | 2 (6) | 14 (17) | 5 (10) | 21 (13) |
| Any treatment-related AE leading to death | 0 | 0 | 0 | 0 |
Data are given as number (percentage) of patients.